Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,861 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,861 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the sale, the general counsel directly owned 21,225 shares in the company, valued at $679,836.75. This represents a 11.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock traded up $0.01 during trading on Tuesday, hitting $32.14. 574,554 shares of the stock were exchanged, compared to its average volume of 816,472. The firm’s 50-day moving average price is $30.81 and its 200 day moving average price is $32.21. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Stoke Therapeutics during the 2nd quarter worth $192,307,000. RTW Investments LP increased its stake in Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after purchasing an additional 423,331 shares during the period. Redmile Group LLC raised its holdings in shares of Stoke Therapeutics by 3.2% in the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after buying an additional 130,050 shares during the last quarter. Morgan Stanley raised its holdings in shares of Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after buying an additional 9,108 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on STOK. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Wedbush lifted their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Guggenheim reissued a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group dropped their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $43.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.